Future studies could evaluate whether the pharmacological induction of SMAD1 expression may represent a therapeutic strategy in KMT2A-rearranged AML with KMT2A::AFF1 and KMT2A::MLLT3 fusion genes. The gene discussed is AFF1; the disease is acute myeloid leukemia.